Last Updated : May 2, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Onivyde | Irinotecan Liposome | Metastatic Pancreatic Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Dysport Therapeutic | abobotulinumtoxinA | Upper limb spasticity | Reimburse with clinical criteria and/or conditions | Complete | ||
Adlyxine | lixisenatide | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Tresiba | insulin degludec | Diabetes mellitus, Type 1 & 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Galafold | migalastat | Fabry Disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Maviret | glecaprevir pibrentasvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
Blincyto | Blinatumomab | Acute Lymphoblastic Leukemia (pediatric) | Reimburse with clinical criteria and/or conditions | Complete | ||
Izba | travoprost ophthalmic solution | Glaucoma and ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
Darzalex | Daratumumab | Multiple Myeloma (second-line) | Reimburse with clinical criteria and/or conditions | Complete | ||
Ocrevus | ocrelizumab | multiple sclerosis, relapsing | Reimburse with clinical criteria and/or conditions | Complete |